Agile’s Low-Dose Birth Control Patch Heads For Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Many women would rather don a weekly patch than remember to take a pill every day, firm says.
You may also be interested in...
New, Existing Players See Opportunity In Crowded Contraceptive Space
With the notable exceptions of Bayer and Johnson & Johnson, big pharma generally does not participate in the contraceptive market. (Merck and Pfizer also are in the market, although their participation occurs on a smaller scale and largely outside the U.S.)
New, Existing Players See Opportunity In Crowded Contraceptive Space
With the notable exceptions of Bayer and Johnson & Johnson, big pharma generally does not participate in the contraceptive market. (Merck and Pfizer also are in the market, although their participation occurs on a smaller scale and largely outside the U.S.)
Contraceptive Patch Maker Agile Recapitalizes With $45 Million Venture Round
Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.